OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 34,305 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,992 shares of the medical technology company's stock after selling 34,305 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Alphatec worth $1,818,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ATEC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alphatec by 3.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,809 shares of the medical technology company's stock valued at $650,000 after acquiring an additional 2,177 shares during the period. Lazard Asset Management LLC bought a new position in shares of Alphatec in the fourth quarter valued at $76,000. Divisadero Street Capital Management LP bought a new stake in Alphatec in the fourth quarter worth about $1,096,000. Bayesian Capital Management LP bought a new stake in shares of Alphatec in the fourth quarter valued at approximately $454,000. Finally, BNP Paribas Financial Markets raised its position in shares of Alphatec by 1,665.1% in the fourth quarter. BNP Paribas Financial Markets now owns 381,324 shares of the medical technology company's stock valued at $3,501,000 after purchasing an additional 359,721 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles sold 32,393 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77. Following the completion of the sale, the chief executive officer now directly owns 5,940,391 shares in the company, valued at $64,690,857.99. The trade was a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Sponsel sold 12,946 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58. Following the completion of the sale, the executive vice president now directly owns 722,128 shares in the company, valued at $7,748,433.44. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,945 shares of company stock valued at $1,416,352. Company insiders own 20.90% of the company's stock.

Alphatec Stock Performance

NASDAQ:ATEC traded down $0.20 during trading hours on Monday, hitting $12.77. 250,544 shares of the company were exchanged, compared to its average volume of 2,031,418. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -9.98 and a beta of 1.06. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.03. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company's 50 day moving average price is $10.73 and its 200-day moving average price is $10.40.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business's revenue for the quarter was up 22.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) earnings per share. As a group, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATEC has been the subject of several research analyst reports. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a report on Friday, May 2nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.